We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · January 18, 2022

Cost-Effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib in BRAF V600 Variation Metastatic Melanoma

JAMA Network Open

 

Additional Info

JAMA Network Open
Estimated Cost-effectiveness of Atezolizumab Plus Cobimetinib and Vemurafenib for Treatment of BRAF V600 Variation Metastatic Melanoma
JAMA Netw Open 2021 Nov 01;4(11)e2132262, C Cai, I Yunusa, A Tarhini

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading